Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...
Eli Lilly has surpassed that S&P 500 five years in a row when Wall Street recognized its enormous opportunity in obesity ...
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) was down 0.2% on Thursday . The company traded as low as $791.50 and last ...
The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
Beginning in March 2025, some patients in Britain will have access to Mounjaro, Eli Lilly’s obesity drug, through the National Health Service (NHS). This follows approval from the UK’s health ...
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback